Posted: Monday, July 17, 2023
For patients with relapsed or refractory multiple myeloma, the use of the B-cell maturation antigen–targeted chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M yielded a median overall survival of 55.8 months, at more than 5 years of follow-up from the phase I LEGEND-2 trial, according to a presentation given at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8010). Specifically, patients who were less heavily pretreated or had a good functional status seemed to benefit the most from this CAR T-cell therapy, according to Jian-Qing Mi, MD, PhD, of the National Research Center for Translational Medicine, Shanghai, China, and colleagues.
From 2016 to 2017, 74 patients with relapsed or refractory multiple myeloma who had previously received treatment with LCAR-B38M CAR T-cell therapy were evaluated 5 years after treatment in the LEGEND-2 study. All patients were also previously treated with lymphodepletion regimens of either cyclophosphamide alone (n = 66) or the combination of cyclophosphamide and fludarabine (n = 8). LCAR-B38M CAR T-cell therapy was delivered as a single infusion (n = 9) or as three separate infusions (n = 65).
Consistent with previous analyses, patients in this cohort had similar rates of complete response (73.0%), overall response (87.8%), measurable residual disease–negative complete response (67.6%), and median progression-free survival (18 months) at the 65.4-month follow-up period. Moreover, no additional CAR T-cell therapy–related adverse events were reported after extended treatment. According to the authors, there was a 55.8-month median overall survival for this patient population. At this time, 44.6% of patients remained alive, and 17.6% were disease-free.
Disclosure: Dr. Mi reported no conflicts of interest. For full disclosures of the other study authors, visit coi.asco.org.